News

Investigators assessed 90-day all-cause mortality between patients with Candida bloodstream infections who did and did not receive an infectious disease consultation.

A total of 543 human cases of West Nile virus disease have been reported to the CDC in 46 states and the District of Columbia as of September 24, 2019.

In part 2 of our Q&A with Fair, we talk about the challenges ahead in the fight against Ebola in the Democratic Republic of the Congo.

As September draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

The NFID released data revealing that only 52% of adults in the United States plan to get vaccinated against the flu this season.

Pharmacists could help improve antibiotic treatment of pediatric patients, particularly in facilities that don’t regularly treat children, according to a recent review article.

STI rates have been growing significantly in the United States and around the world. To fix the problem, we need a renewed focus on this therapeutic area, according to top public health officials.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of September 22, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Use of high-risk antibiotics is linked to C diff infections, but the class of antibiotics with the strongest link has changed over time underscoring the need for ongoing assessment.

The Contagion® editorial staff will be providing exclusive written and video coverage from IDWeek 2019.

According to results from the Rwanda Population-based HIV Impact Assessment (RPHIA), 76% of all adults living with HIV in Rwanda have achieved viral load suppression.

The FDA has approved treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to 8 weeks.

A hospital sheds light on how dogs can help identify C diff contamination.

Investigators of a new study assessed data from a 14-year-period and found that the prevalence ratio for heart infections related to drug abused jumped from 8% to 16%.

Investigators used national electronic health record data to determine the proportion of American adults who have been tested for HIV.

A human vaccine could reach clinical trials in 2 years, the lead researcher told Contagion®.

Editing out a particular gene located inside cells has big implications for the weakening of the common cold virus along with more dangerous infectious agents.

Amid growing reports of viral resistance in patients living with HIV, IDSA, HIV Medicine Association, and American Academy of HIV Medicine have issued a joint policy paper.

The storm damaged multiple public health clinics and vector-borne diseases remain a concern, per a PAHO/WHO report.

In part 1 of our Q&A with Fair, we talk about his background, education, and experience, and also how the outbreak response to the current Ebola outbreak in the DRC differs from traditional disaster response.

The approval marks the first FDA-approved, non-replicating smallpox vaccine, and the only FDA-approved vaccine for prevention of monkeypox.

The vaccine, manufactured by Johnson & Johnson, is administered in 2 doses, 56 days apart and will be used in areas that are not experiencing active transmission.

Long-term immunogenicity of a 2-dose schedule of the quadrivalent HPV vaccination was demonstrated in a new study in Canada that followed up on an earlier clinical trial.

USPSTF has downgraded its recommendation regarding the screening of pregnant women for asymptomatic bacteriuria, based on reduced applicability of the previous evidence.

A new paper offers a compelling theory as to why it takes so long for antibiotics to defeat tuberculosis.

A 10th human case of EEE in Massachusetts has also become the state’s second fatality, the state Department of Public Health has announced.

A National Influenza Vaccine Task Force has been established, which will develop a 5-year plan to promote new vaccine manufacturing technology and to accelerate the development of a universal flu vaccine.